Pharmaceutical Research

If your manuscript has been declined, and you are planning to submit your article to another of the four AAPS journals (AAPS Open, The AAPS Journal, AAPSPharmSciTech, or Pharmaceutical Research), we can help make the peer review process faster and smoother by extending the use of previous peer reviewer comments! Portable Peer Review, an opt-into service available for any author of these journals, allows us to share, between the portfolio, previous peer review comments and reviewer names, subject to approval of all parties. This can help speed up the assessment process, should the editor choose to make a decision on the basis of the comments and revision. Interested?  Email us with the name of the journal to which you are going to submit. Note: Portable peer review is opt-in only, available at the authors’ preference, and the reviewer identities and comments will only be shared between offices, not to the author.

AAPS Pharmaceutical Research Meritorious Manuscript Award Recognizing outstanding achievement in the pharmaceutical sciences as demonstrated by the author(s) in the quality and originality of a manuscript published in Pharmaceutical Research.  Watch the video here.

Awardee/Corresponding Author: Dennis Douroumis, Ph.D., University of Greenwich Co-Authors: Nicolaos Scoutaris, Ph.D. and Steven A. Ross, Ph.D.

Repurposing of kinase inhibitors for treatment of COVID-19
There are three major needs that have yet to be met for effective management of COVID19 disease: 1) anti-viral therapies that limit viral transmission, cell entry, and replication, 2) therapies that attenuate the non-productive immune response and thus decrease end-organ damage, and 3) therapies that have an anti-fibrotic effect in patients with ARDS and thus decrease long-term sequelae of disease. Read the article above for the full review and proposal.

AAPS Open is proud to announce new Editor-in-Chief Dr. Andrea Allmendinger. Dr. Allmendinger obtained her PhD in Pharmaceutical Technology from the University of Basel and joined the Pharmaceutical Development department of Roche/Genentech in Basel in 2013, where she is responsible for formulation and process development for clinical Phase I-III projects and commercial transfer activities for both large molecules and for synthetic drugs.